CD274 and neoplasm: Promising interim results of a currently ongoing phase II trial assessing a triple combination of an HPV 16 E6/7 based vaccine, a tumor-targeting IL12 immunocytocine and bintrafusp alfa (a PD-L1 and TGF-ß inhibitor) in patients with advanced, previously treated cervical, anal, head and neck, vulvar and vaginal cancer (n = 25) were recently presented at the ASCO Annual Meeting 2021.